Stiina Aarum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stiina Aarum has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Sepodes
The Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, the Netherlands
3 shared publications - Kerstin Westermark
Läkemedelsverket, Uppsala, Sweden
3 shared publications - Laura Fregonese
Orphan Medicines Office, European Medicines Agency, London, UK
3 shared publications - Segundo Mariz
Orphan Medicines Office, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, NETHERLANDS
3 shared publications - Stelios Tsigkos
Orphan Medicines Office, European Medicines Agency, Amsterdam, Netherlands
3 shared publications - Frauke Naumann-Winter
Federal Institute for Drugs and Medical Devices, Bonn, Germany
2 shared publications
Latest Publications
- Open Access
- 10 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1593644
Multistakeholder scientific advice for medicinal products used in combination with a medical device or a companion diagnostic in the EU—summary of a Focus group discussion
Although there is growing use of medicinal products in combination with medical devices, including in vitro diagnostics (IVDs) and software as a medical device, their development in the EU is proving to be more challenging due to the complexities in working across the regulatory frameworks for medicinal products, medical devices and IVDs. One of the concerns is the lack of a multistakeholder platform [European Medicines Agency (EMA)/Scientific Advice Working Party (SAWP); National Competent Authorities (NCAs) in charge of medicinal products; NCAs for medical devices; notified bodies (NBs)] for scientific and regulatory advice on medicinal products used in combination with medical devices or IVDs [including companion diagnostics (CDx)]. A multistakeholder platform would allow for an opportunity to discuss the scientific expectations of the different decision makers involved and guide the identification of an appropriate development path for both medicine and medical device/IVD (including CDx). In search of a pragmatic approach to facilitate discussions on evidence generation plans, it was agreed in the “9th EMA-Industry stakeholder platform on research and development support” meeting in December 2022 to set up a dedicated Focus group to determine the possibility of provision of scientific advice for medicinal products in combination with a medical device or IVD (including CDx). The Focus group had participants from the EMA SAWP, the NCAs, the NBs, and industry and the EMA. The group explored what kind of scientific questions would benefit from being addressed in comprehensive discussions on evidence generation planning in a multistakeholder setting, and who would be the required decision makers and experts for such multidisciplinary discussions. The discussions covered nine study cases: four were drug-device combinations and five were drug—IVD/CDx combinations. The scope of the discussions excluded stand-alone high-risk medical devices and IVDs for which there was an ongoing scientific advice pilot involving the medical device expert panels. In addition, low-risk stand-alone medical device/IVD developments were also out-of-scope. This article presents the insights of the discussions on the nine study cases reviewed by the Focus group and explores options for next steps to inform future policy and technical discussions on these innovative healthcare developments.
- 10 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1593644
Open AccessMultistakeholder scientific advice for medicinal products used in combination with a medical device or a companion diagnostic in the EU—summary of a Focus group discussion
Although there is growing use of medicinal products in combination with medical devices, including in vitro diagnostics (IVDs) and software as a medical device, their development in the EU is proving to be more challenging due to the complexities in working across the regulatory frameworks for medicinal products, medical devices and IVDs. One of the concerns is the lack of a multistakeholder platform [European Medicines Agency (EMA)/Scientific Advice Working Party (SAWP); National Competent Authorities (NCAs) in charge of medicinal products; NCAs for medical devices; notified bodies (NBs)] for scientific and regulatory advice on medicinal products used in combination with medical devices or IVDs [including companion diagnostics (CDx)]. A multistakeholder platform would allow for an opportunity to discuss the scientific expectations of the different decision makers involved and guide the identification of an appropriate development path for both medicine and medical device/IVD (including CDx). In search of a pragmatic approach to facilitate discussions on evidence generation plans, it was agreed in the “9th EMA-Industry stakeholder platform on research and development support” meeting in December 2022 to set up a dedicated Focus group to determine the possibility of provision of scientific advice for medicinal products in combination with a medical device or IVD (including CDx). The Focus group had participants from the EMA SAWP, the NCAs, the NBs, and industry and the EMA. The group explored what kind of scientific questions would benefit from being addressed in comprehensive discussions on evidence generation planning in a multistakeholder setting, and who would be the required decision makers and experts for such multidisciplinary discussions. The discussions covered nine study cases: four were drug-device combinations and five were drug—IVD/CDx combinations. The scope of the discussions excluded stand-alone high-risk medical devices and IVDs for which there was an ongoing scientific advice pilot involving the medical device expert panels. In addition, low-risk stand-alone medical device/IVD developments were also out-of-scope. This article presents the insights of the discussions on the nine study cases reviewed by the Focus group and explores options for next steps to inform future policy and technical discussions on these innovative healthcare developments.
- Open Access
- 1 February 2018
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (2) , 424-433
Marketing authorisation of orphan medicines in Europe from 2000 to 2013
- 1 February 2018
- Published by Elsevier in Drug Discovery Today
- Vol. 23 (2) , 424-433
Open AccessMarketing authorisation of orphan medicines in Europe from 2000 to 2013
- Open Access
- 6 October 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1
Erratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union
- 6 October 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1
Open AccessErratum to: Establishing medical plausibility in the context of orphan medicines designation in the European Union
- Open Access
- 5 December 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 175
Establishing medical plausibility in the context of orphan medicines designation in the European Union
In the European Union, sponsors have the responsibility to demonstrate the “intention to diagnose, prevent or treat” a serious and rare condition before the Committee of Orphan Medicinal Products (COMP), for a medicinal product to meet the criteria for Orphan Designation. This requirement is commonly referred to as “medical plausibility” and the justification of this intention is assessed on the merits of each application by the COMP, which deliberates over the scientific evaluation of the evidence submitted. The scientific assessment of the applications for orphan designation by the Committee is based on the review of non-clinical (such as in vitro and in vivo) and/or clinical data submitted by the sponsor. Several challenges regarding the evidence provided emerge when the sponsor is applying for a designation at an early stage of development. Herein we discuss specific examples from the experience of the COMP, in order to elaborate on the type and level of evidence generally considered necessary for the purpose of justification of the intention to treat an orphan condition. Importantly, it is pointed out that bridging of data from other products, irrespectively of how comparable they may be, or from settings not directly associated with the condition as applied for designation, is by and large not a successful exercise and may only be exceptionally considered. It is further exemplified that, as reflected in the updated ‘Guideline on the format and context of the applications for designation’ and the guidance document ‘Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation’ available on the EMA website, the sponsor should provide data with the specific product as applied for in specific models of the condition or in patients affected by the same condition subject of each application.
- 5 December 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 175
Open AccessEstablishing medical plausibility in the context of orphan medicines designation in the European Union
In the European Union, sponsors have the responsibility to demonstrate the “intention to diagnose, prevent or treat” a serious and rare condition before the Committee of Orphan Medicinal Products (COMP), for a medicinal product to meet the criteria for Orphan Designation. This requirement is commonly referred to as “medical plausibility” and the justification of this intention is assessed on the merits of each application by the COMP, which deliberates over the scientific evaluation of the evidence submitted. The scientific assessment of the applications for orphan designation by the Committee is based on the review of non-clinical (such as in vitro and in vivo) and/or clinical data submitted by the sponsor. Several challenges regarding the evidence provided emerge when the sponsor is applying for a designation at an early stage of development. Herein we discuss specific examples from the experience of the COMP, in order to elaborate on the type and level of evidence generally considered necessary for the purpose of justification of the intention to treat an orphan condition. Importantly, it is pointed out that bridging of data from other products, irrespectively of how comparable they may be, or from settings not directly associated with the condition as applied for designation, is by and large not a successful exercise and may only be exceptionally considered. It is further exemplified that, as reflected in the updated ‘Guideline on the format and context of the applications for designation’ and the guidance document ‘Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation’ available on the EMA website, the sponsor should provide data with the specific product as applied for in specific models of the condition or in patients affected by the same condition subject of each application.
- Open Access
- 1 January 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 13
Use of biomarkers in the context of orphan medicines designation in the European Union
The use of biomarkers within the procedures of the Committee of Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) is discussed herein. The applications for Orphan Medicinal Product designation in the EU are evaluated at two stages. At the time of orphan designation application, the file undergoes an assessment to establish whether the proposed condition is a distinct and serious condition affecting not more than 5 in 10,000 people in the EU, and whether the product is plausible as a therapy for that condition. In cases where therapies already exist, the significant benefit of the candidate product over existing therapies is also evaluated. The orphan criteria are reassessed at the time of marketing authorisation, so that marketing exclusivity for the product in the orphan medical condition can be granted. Within this context, biomarkers have been used in submissions in order to define an orphan condition and to justify that the criteria for orphan designation are met. The current work discusses specific examples from the experience of the COMP, where biomarkers have played a decisive role. Importantly, it identifies the proposal of sub-sets of non-rare conditions based on biomarkers as a challenging issue in the evaluation of applications. In particular two specific requirements for the candidate orphan medicines in relation to the biomarker-based subsets are highlighted: the “plausible link to the condition” and the “exclusion of effects outside the subset”.
- 1 January 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 13
Open AccessUse of biomarkers in the context of orphan medicines designation in the European Union
The use of biomarkers within the procedures of the Committee of Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) is discussed herein. The applications for Orphan Medicinal Product designation in the EU are evaluated at two stages. At the time of orphan designation application, the file undergoes an assessment to establish whether the proposed condition is a distinct and serious condition affecting not more than 5 in 10,000 people in the EU, and whether the product is plausible as a therapy for that condition. In cases where therapies already exist, the significant benefit of the candidate product over existing therapies is also evaluated. The orphan criteria are reassessed at the time of marketing authorisation, so that marketing exclusivity for the product in the orphan medical condition can be granted. Within this context, biomarkers have been used in submissions in order to define an orphan condition and to justify that the criteria for orphan designation are met. The current work discusses specific examples from the experience of the COMP, where biomarkers have played a decisive role. Importantly, it identifies the proposal of sub-sets of non-rare conditions based on biomarkers as a challenging issue in the evaluation of applications. In particular two specific requirements for the candidate orphan medicines in relation to the biomarker-based subsets are highlighted: the “plausible link to the condition” and the “exclusion of effects outside the subset”.